GENE ONLINE|News &
Opinion
Blog

2022-09-21| R&D

Promising CHIP Protein Could Act as ‘Molecular Switch’ to Longevity

by Nai Ye Yeat
Share To

Researchers from the University of Cologne reported that a single protein could modulate aging signals more effectively compared to a group of proteins. According to their recent publication, the team has discovered the protein CHIP (carboxy-terminus of Hsc70-interacting protein) can control life-prolonging signals such as insulin receptors in the cell more efficiently alone than in a paired state. The journal Molecular Cell published the results on August 25. 

Related Article: Human Skin Cells Reprogramming Creates New Neurodegenerative Model For Huntington’s Disease

Monomer-Dimer Conversion of CHIP

Under cellular stress situations, protein CHIP usually appears as a homodimer, an association of two identical proteins, and primarily serves to degrade misfolded or defective proteins to clean up the cell. It will collaborate with helper proteins to attach a chain of the small, regulatory protein, ubiquitin, to misfolded or defective proteins. The labeled proteins are then recognized and eliminated. Moreover, CHIP also regulates the signal transduction of the insulin receptor by binding ubiquitin to the receptor to degrade it and stop the activation of life-extending gene products.

In the recent study led by Professor Dr. Thorsten Hoppe, the team used nematode Caenorhabditis elegans and human cells as models. It successfully showed that CHIP not only labels others but also labels itself with ubiquitin to prevent its dimer formation. Surprisingly, the CHIP monomer is more efficient than the CHIP dimer in regulating insulin signaling.

However, scientists found that whether CHIP works alone or as a pair depends on the state of the cell. For instance, under stress conditions, too many misfolded proteins and helper proteins bind to CHIP and prevent auto-ubiquitylation (the self-labeling of CHIP with ubiquitin). After CHIP successfully cleans up the defective proteins, it can also mark the helper proteins for degradation, allowing CHIP to ubiquitylate itself and function as a monomer again. To ensure the process functions smoothly, the scientists hypothesized there must be a balance between the monomeric and dimeric states of CHIP. 

Setting the Stage for a New Class of Targeted Therapies

The disrupted monomer-dimer balance of CHIP in neurodegenerative diseases grabs the attention of scientists. For instance, in the case of Alzheimer’s Disease, the most common neurodegenerative disease worldwide, its pathology is closely related to beta-amyloid (Aβ) deposits and hyperphosphorylated tau(p-tau). Several studies have reported that CHIP can directly ubiquitinate and eliminate p-tau, while in vivo studies also showed that overexpressing CHIP could reduce tau phosphorylation. 

To sum up, the expression level of CHIP is extremely important to develop novel targeted therapy. The next step for scientists is to determine whether there are any further proteins or receptors that the CHIP monomer interacts with and regulates their function subsequently. The concentrations of CHIP monomers or dimers in different tissues, organs, and diseases are also left to be identified.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
An Updated View on the “Central Dogma” of Molecular Biology
2023-01-03
DeepMind’s AlphaFold Predicts Over 200 Million Protein Shapes in AI Breakthrough
2022-08-01
Why CRY2 matters: Studying Control of Plants and Human Growth
2022-06-20
LATEST
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
EVENT
Scroll to Top